Kane Biotech Announces Positive Results From an Independent Wound Care Study Kane Biotech Inc. (TSX VENTURE:KNE), a biotechnology company engaged in the development of products that prevent and disperse microbial biofilms, is pleased to announce positive results from an in vitro study using a novel approach to treat chronic wound infections with a combination of DispersinB and lytic bacteriophage.
The study carried out by Dr. Randy Wolcott's team at the Southwest Regional Wound Care Center in Lubbock, Texas, showed that the combination of DispersinB with a bacteriophage mixture was very effective against biofilm-embedded E.coli. More specifically, the DispersinB and bacteriophage mixture showed almost 99% inhibition of E.coli growth and proliferation as compared to only 9% inhibition by the bacteriophage mixture alone over the four day period of treatment. While DispersinB makes biofilm-embedded bacteria more susceptible to bacteriophage by inhibiting or dispersing biofilms, lytic bacteriophage invades bacterial cells and disrupts the metabolism of the bacteria. This combination therapy could provide a new and highly effective method of treating chronic wounds such as diabetic foot ulcers. More here: http://www.arizonabiotech.com/2007/07/kane-biotech-announces-positive-results.html
